FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2895964268> ?p ?o ?g. }

• W2895964268 endingPage "521" @default.
• W2895964268 startingPage "515" @default.
• W2895964268 abstract "Graft-versus-host disease (GVHD) remains the most common treatment-related complication after allogeneic hematopoietic cell transplantation (allo-HCT). Lymphocyte migration plays a critical role in the pathogenesis of GVHD. A previous phase I/II trial demonstrated that CCR5 blockade with maraviroc in the first 30days after allo-HCT resulted in a low incidence of early acute GVHD, primarily in visceral organs, but with no impact on late acute or chronic GVHD.We conducted a phase II trial to examine the efficacy of an extended course of maraviroc, administered through post-transplantation day +90 in addition to standard prophylaxis in 37 recipients of reduced-intensity-conditioned unrelated donor allo-HCT performed to treat hematologic malignancies.Extended maraviroc treatment was safe and feasible. The primary study endpoint, day +180 rate of grade II-IV acute GVHD, was 22 ± 7%, liver GVHD was not observed, and gut GVHD was uncommon. The day +180 rate of grade III-IV acute GVHD was 5 ± 4%. The 1-year rate of moderate to severe chronic GVHD was 8 ± 5% and that of disease relapse was 30 ± 8%. Overall survival at 1 year was 70 ± 8%. Compared with the previously studied short course of maraviroc, the extended course resulted in a significantly higher GVHD-free, relapse-free survival (adjusted hazard ratio [HR], .45; 95% confidence interval [CI], .25 to .82; P = .009) and overall survival (adjusted HR, .48; 95% CI, .24 to .96; P = .037). A combined analysis of both trials showed that high maraviroc trough concentrations on the day of hematopoietic cell infusion were associated with lower rates of acute GVHD.An extended course of maraviroc after reduced-intensity-conditioned unrelated donor allo-HCT is safe and effective in preventing acute and chronic GVHD and is associated with favorable survival." @default.
• W2895964268 created "2018-10-26" @default.
• W2895964268 creator A5003280424 @default.
• W2895964268 creator A5014838335 @default.
• W2895964268 creator A5017415232 @default.
• W2895964268 creator A5023287139 @default.
• W2895964268 creator A5029801761 @default.
• W2895964268 creator A5040750947 @default.
• W2895964268 creator A5041976525 @default.
• W2895964268 creator A5045895388 @default.
• W2895964268 creator A5050265278 @default.
• W2895964268 creator A5052264374 @default.
• W2895964268 creator A5068899023 @default.
• W2895964268 creator A5074792801 @default.
• W2895964268 creator A5085167557 @default.
• W2895964268 creator A5089409657 @default.
• W2895964268 creator A5091612581 @default.
• W2895964268 creator A5091661654 @default.
• W2895964268 date "2019-03-01" @default.
• W2895964268 modified "2023-10-14" @default.
• W2895964268 title "Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial" @default.
• W2895964268 cites W1513106126 @default.
• W2895964268 cites W1533267916 @default.
• W2895964268 cites W1921369055 @default.
• W2895964268 cites W1964616348 @default.
• W2895964268 cites W1976161748 @default.
• W2895964268 cites W2005134899 @default.
• W2895964268 cites W2006427551 @default.
• W2895964268 cites W2010221217 @default.
• W2895964268 cites W2010438746 @default.
• W2895964268 cites W2019111335 @default.
• W2895964268 cites W2034952320 @default.
• W2895964268 cites W2043608152 @default.
• W2895964268 cites W2045254759 @default.
• W2895964268 cites W2046963419 @default.
• W2895964268 cites W2048453798 @default.
• W2895964268 cites W2055254092 @default.
• W2895964268 cites W2056305086 @default.
• W2895964268 cites W2056978918 @default.
• W2895964268 cites W2057589913 @default.
• W2895964268 cites W2064085613 @default.
• W2895964268 cites W2065948425 @default.
• W2895964268 cites W2066052563 @default.
• W2895964268 cites W2116455112 @default.
• W2895964268 cites W2120233660 @default.
• W2895964268 cites W2131122030 @default.
• W2895964268 cites W2131751704 @default.
• W2895964268 cites W2134990960 @default.
• W2895964268 cites W2162037969 @default.
• W2895964268 cites W2164491214 @default.
• W2895964268 cites W2234054426 @default.
• W2895964268 cites W2331667420 @default.
• W2895964268 cites W2379365975 @default.
• W2895964268 cites W2483074078 @default.
• W2895964268 cites W2569245659 @default.
• W2895964268 cites W2620574049 @default.
• W2895964268 cites W2765736682 @default.
• W2895964268 cites W2767662007 @default.
• W2895964268 cites W2780122844 @default.
• W2895964268 cites W2783813772 @default.
• W2895964268 cites W2883090557 @default.
• W2895964268 doi "https://doi.org/10.1016/j.bbmt.2018.09.034" @default.
• W2895964268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6445759" @default.
• W2895964268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30315941" @default.
• W2895964268 hasPublicationYear "2019" @default.
• W2895964268 type Work @default.
• W2895964268 sameAs 2895964268 @default.
• W2895964268 citedByCount "20" @default.
• W2895964268 countsByYear W28959642682019 @default.
• W2895964268 countsByYear W28959642682020 @default.
• W2895964268 countsByYear W28959642682021 @default.
• W2895964268 countsByYear W28959642682022 @default.
• W2895964268 countsByYear W28959642682023 @default.
• W2895964268 crossrefType "journal-article" @default.
• W2895964268 hasAuthorship W2895964268A5003280424 @default.
• W2895964268 hasAuthorship W2895964268A5014838335 @default.
• W2895964268 hasAuthorship W2895964268A5017415232 @default.
• W2895964268 hasAuthorship W2895964268A5023287139 @default.
• W2895964268 hasAuthorship W2895964268A5029801761 @default.
• W2895964268 hasAuthorship W2895964268A5040750947 @default.
• W2895964268 hasAuthorship W2895964268A5041976525 @default.
• W2895964268 hasAuthorship W2895964268A5045895388 @default.
• W2895964268 hasAuthorship W2895964268A5050265278 @default.
• W2895964268 hasAuthorship W2895964268A5052264374 @default.
• W2895964268 hasAuthorship W2895964268A5068899023 @default.
• W2895964268 hasAuthorship W2895964268A5074792801 @default.
• W2895964268 hasAuthorship W2895964268A5085167557 @default.
• W2895964268 hasAuthorship W2895964268A5089409657 @default.
• W2895964268 hasAuthorship W2895964268A5091612581 @default.
• W2895964268 hasAuthorship W2895964268A5091661654 @default.
• W2895964268 hasBestOaLocation W28959642681 @default.
• W2895964268 hasConcept C126322002 @default.
• W2895964268 hasConcept C141071460 @default.
• W2895964268 hasConcept C203014093 @default.
• W2895964268 hasConcept C203092338 @default.
• W2895964268 hasConcept C207103383 @default.
• W2895964268 hasConcept C2777408962 @default.
• W2895964268 hasConcept C2778899366 @default.

• next